SCHEMBL403165

SCHEMBL403165

C#Cc1ccc(C(N)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 10/20 0.50
PARP15 Q460N3 3/20 0.50
PARP2 Q9UGN5 2/20 0.50
PARP4 Q9UKK3 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 1/20 0.48
PARP14 Q460N5 1/20 0.48
PARP16 Q8N5Y8 1/20 0.48
PARP11 Q9NR21 1/20 0.48
PARP1 P09874 2/20 0.48
POLB P06746 2/20 0.48
TSHR P16473 2/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31371753 0.94 CA12 (0.50) PARP10PARP15PARP2PARP4ALDH1A1
Formic Acid SCHEMBL28050738 0.92 PARP10 (0.44) PARP10PARP15PARP2PARP4ALDH1A1
Benzamide SCHEMBL28005389 0.85 PARP1 (0.67) PARP10ALDH1A1PARP1POLBTSHR
SCHEMBL16595892 0.82 CA1 (0.42) PARP10PARP15PARP2ALDH1A1POLB
SCHEMBL28255744 0.80 PARP10 (0.53) PARP10PARP15PARP2PARP4ALDH1A1
SCHEMBL3838955 0.80 SRD5A2 (0.48) ALDH1A1MAPTCA2CA1CA12
SCHEMBL13582530 0.80 CES2 (0.48) CA2CA1CA12CA4CA9
Terephthalamide SCHEMBL23774 0.79 PARP1 (0.71) PARP10PARP15PARP2PARP4ALDH1A1
SCHEMBL4757633 0.78 PARP10 (0.52) PARP10PARP15PARP2PARP4ALDH1A1
SCHEMBL40299 0.78 TSHR (0.60) ALDH1A1TSHRCA2CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119463156-A Amphiphilic organic near-infrared thermal activation delayed fluorescence molecule and preparation method and application thereof 内蒙古大学 2025-02-18 CN claimed
CN-116375549-A Method and system for synthesizing amide compound from nitrile compound 深圳湾实验室 2023-07-04 CN claimed
US-7009052-B2 Sulfonamide derivatives WARNER LAMBERT COMPANY LLC (US) 2006-03-07 US claimed
US-20050004367-A1 Sulfonamide derivatives DU DANIEL Y (US) 2005-01-06 US claimed
WO-2025098545-A1 NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) 2025-05-15 WO disclosed
EP-4553080-A1 NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2025-05-14 EP disclosed
CN-119463156-A Amphiphilic organic near-infrared thermal activation delayed fluorescence molecule and preparation method and application thereof 内蒙古大学 2025-02-18 CN disclosed
CN-119463156-A Amphiphilic organic near-infrared thermal activation delayed fluorescence molecule and preparation method and application thereof 内蒙古大学 2025-02-18 CN disclosed
CN-114773301-B Method for synthesizing furan compounds from terminal alkyne and iodoylide 南方医科大学 2024-01-05 CN disclosed
CN-117098750-A Molecules having pesticidal utility, and intermediates and methods related thereto 科迪华农业科技有限责任公司 2023-11-21 CN disclosed
CN-116375549-A Method and system for synthesizing amide compound from nitrile compound 深圳湾实验室 2023-07-04 CN disclosed
EP-3625218-B1 PROCESS FOR HYDROCYANATION OF TERMINAL ALKYNES STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-03-01 EP disclosed
EP-1608643-A1 6-SULFONAMIDE QUINOLINE AND CHROMENE DERIVATIVE AS ANDROGEN RECEPTOR ANTAGONISTS Warner-Lambert Company LLC (US) 2005-12-28 EP disclosed
US-20050004367-A1 Sulfonamide derivatives DU DANIEL Y (US) 2005-01-06 US disclosed
US-20040229955-A1 intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, UNIVERSITY OF WASHINGTON 2004-11-18 US disclosed
WO-2004083204-A1 6-SULFONAMIDE QUINOLINE AND CHROMENE DERIVATIVE AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-09-30 WO disclosed
WO-2004062601-A2 ANTIBACTERIAL AGENTS CHIRON CORPORATION (US) 2004-07-29 WO disclosed
US-6384235-B2 BY CYCLIZATION OF ALKYNYLAMINOAROMATIC, POSSIBLY ATTACHED TO CARRIER, IN POLAR APROTIC SOLVENT WITH ALKALI METAL COMPOUND; DRUG SYNTHESIS BASF AKTIENGESELLSCHAFT (DE) 2002-05-07 US disclosed
US-20010037031-A1 Preparation of substituted indoles BASF AKTIENGESELLSCHAFT (DE) 2001-11-01 US disclosed
EP-1127874-A2 Process for the preparation of substituted indoles BASF AKTIENGESELLSCHAFT (DE) 2001-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229955-A1 intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, PDF, DDOST, MRPL21 PARP10 2286/4885PARP15 2314/4885PARP2 3219/4885
US-20050004367-A1 Sulfonamide derivatives AR, SULT2A1, SHBG PARP10 836/4885PARP15 904/4885PARP2 2424/4885
US-20010037031-A1 Preparation of substituted indoles AHR, CYP2S1, CBR1 PARP10 2130/4885PARP15 2335/4885PARP2 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.